HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.
Breast Cancer Res
; 22(1): 15, 2020 01 31.
Article
em En
| MEDLINE
| ID: mdl-32005279
ABSTRACT
BACKGROUND:
There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).METHODS:
Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.RESULTS:
We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. We review biological findings underlying HER2 heterogeneity and its implication in the development of novel anti-HER2 drugs including new ADCs in clinical development like trastuzumab deruxtecan (DS-8201).CONCLUSIONS:
We suggest potential mechanisms to optimize these compounds and their future clinical implementation.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Receptor ErbB-2
/
Imunoconjugados
/
Resistencia a Medicamentos Antineoplásicos
/
Evolução Clonal
Limite:
Female
/
Humans
Idioma:
En
Revista:
Breast Cancer Res
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Espanha